Manisha S. Jain, Samathoti Prasanthi, Nirmala Devi Bommala, Prakash Goudanavar and N. Raghavendra Naveen* Pages 1 - 13 ( 13 )
The human gut microbiome has emerged as a crucial component of health and disease, presenting novel opportunities for the development of drug delivery systems based on microbiome interactions. This paper explores advanced strategies utilizing microorganisms, engineered bacteria, viruses, and bacteria-encapsulated nanoparticles as next-generation therapeutic vehicles. Focusing on analytical approaches to phage therapy and bio-hybrid bacteria for targeted drug delivery, the article highlights recent breakthroughs in colon-specific targeting for gastrointestinal disorders. The study also delves into the emerging field of pharmacomicrobiomics, with an emphasis on applications in cancer, cardiovascular, digestive, and nervous system treatments, specifically targeting key drug classes such as ACE inhibitors, proton-pump inhibitors, and NSAIDs. Challenges related to cytotoxicity and toxicity are addressed, offering proposals for safer therapeutic applications. This review underscores the transformative potential of the microbiome in personalized medicine and targeted drug delivery, with a focus on its integration with advanced technologies to optimize therapeutic outcomes.
Human gut microbiome, drug delivery systems, pharmacomicrobiomics, microbiome-targeted therapy, virus-based drug delivery, bacteria-encapsulated nanoparticles, proteinaceous drugs, reactive oxygen species, synthetic biology, microbiome engineering.